(10)

(19) JAPANESE PATENT OFFICE

PATENT ABSTRACTS OF JAPAN

(11) Publication number: **06072868 A**
(43) Date of publication of application: **15.03.1994**

(51) Int. Cl **A61K 31/20**
A61K 31/23, C07C 59/42, C07C 69/587, C07C233/09, C07F 9/10
// C07C 57/03

(21) Application number: **04227510**
(22) Date of filing: **26.08.1992**

(71) Applicant: **MARUHA CORP**
(72) Inventor: **NISHIKAWA MASAZUMI**
KIMURA SEIJI

(54) ANTIPSYCHOTIC AGENT

(57) Abstract:

PURPOSE: To obtain an antipsychotic agent, comprising docosahexaenoic acid (derivative) as an active ingredient and excellent in safety and therapeutic effects.

CONSTITUTION: The objective antipschotic agent comprises one or more of docosahexaenoic acid (derivative) such as a lipoxygenase metabolite as an active ingredient. Furthermore, this antipsychotic agent is perorally administered to an adult in a daily dose of preferably 300-1800mg expressed in terms of the active ingredient in the case of oral administration.

XP-002092998

1/1 - (C) WPI / DERWENT
AN - 94-128761 ç16!
AP - JP920227510 920826
PR - JP920227510 920826
TI - Antipsychotic agents - contain docosahexaenoic acid (deriv)
IW - ANTIPSYCHOTIC AGENT CONTAIN ACID DERIVATIVE
PA - (TAIF) MARUHA KK
PN - JP6072868 A 940315 DW9416 A61K31/20 005pp
ORD - 1994-03-15
IC - A61K31/20 ; A61K31/23 ; C07C57/03 ; C07C59/42 ; C07C69/587 ; C07C233/09 ; C07F9/10
FS - CPI
DC - B05
AB - J06072868 Antipsychotic agents contain one or more of docosahexaenoic acid (I) and its derivs. as effective component.
- (I) derivs. are fatty acids, phospholipids, or triglycerides. (I) derivs. are salts, amides, or esters. (I) derivs. are lipoxygenase metabolites or their derivs. (I) derivs. are P450 dehydrogenase metabolites or their derivs.
- The daily dose of (I) or its derivs. is 300-1800 mg/adult and 50-300 mg/adult when administered orally or by injection, respectively.
- USE/ADVANTAGE - The agents, which are of low toxicity, are useful in the treatment and prevention of mental disorders.
- In an example, it was found that the action of phencyclidine on the N-methyl-D-aspartic acid receptor was decreased by 30 uM (I) in electrophysiological test using rat brain cells previously treated with 5 uM phencyclidine and 30 uM N-methyl-D-aspartic acid. Detected lipoxygenase metabolites of (I) were 1 uM 14-hydroxy- and 1 uM 7-hydroxy-(I) and a detected P450 dehydrogenase metabolite of (I) was 1 uM 7,8-epoxydocosapentaenoic acid. The results suggested that (I) and its metabolites may prevent or improve psychotic diseases including schizophrenia. The clinical effecacy of (I) was recognized in a placebo test in that 300mg (I) ethyl ester was administered 3 times a day to 8 schizophrenic patents, 6 of them showing improvement.(Dwg.0/0)